US nod for CSL Behring’s HAE prevention therapy

23rd June 2017 Uncategorised 0

US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adults

More: US nod for CSL Behring’s HAE prevention therapy
Source: News